Update by Goldman Goldman Small Cap Research Re
Post# of 36566
(Total Views: 209)
Posted On: 11/30/2018 10:42:14 AM
Update by Goldman
Goldman Small Cap Research Report Highlights
In the Opportunity Research update, analyst Rob Goldman discusses Generex’s recent events and exciting upcoming opportunities that lie ahead.
Goldman noted, “Since our coverage initiation earlier this month, GNBT has announced a series of deals that should serve as a precursor to revenue and valuations gains in 2019. The Company continues to execute on its strategy to become a nationwide, integrated, end-to-end health care firm. GNBT has signed a LOI with 2 firms, in which the Company will own 51%. Both deals should close this quarter and a tender for the remaining 49% could occur next year. These transactions will give GNBT exposure to the $23B wound care market via a platform device that is cleared for 17 indications, including diabetic ulcers, and the multi-billion-dollar ulcerative colitis market via a pending 510(k) De Novo submission and trial. Each of these categories represents favorable valuations, which could be unlocked, beginning next year.”
“The Company’s new CBD Product Agreement with Puration is game-changing. GNBT will be introducing NuGenerex CBD HydroHealth High Alkaline Water to its patient population and ever-growing pharmacy network. This high value new offering will be infused with custom CBD extracts as therapies for symptoms of specific health issues. “
Goldman concluded, “The aforementioned business development events projects affirm our favorable outlook on these shares and we continue to expect a higher overall valuation ahead for GNBT.”
Goldman Small Cap Research Report Highlights
In the Opportunity Research update, analyst Rob Goldman discusses Generex’s recent events and exciting upcoming opportunities that lie ahead.
Goldman noted, “Since our coverage initiation earlier this month, GNBT has announced a series of deals that should serve as a precursor to revenue and valuations gains in 2019. The Company continues to execute on its strategy to become a nationwide, integrated, end-to-end health care firm. GNBT has signed a LOI with 2 firms, in which the Company will own 51%. Both deals should close this quarter and a tender for the remaining 49% could occur next year. These transactions will give GNBT exposure to the $23B wound care market via a platform device that is cleared for 17 indications, including diabetic ulcers, and the multi-billion-dollar ulcerative colitis market via a pending 510(k) De Novo submission and trial. Each of these categories represents favorable valuations, which could be unlocked, beginning next year.”
“The Company’s new CBD Product Agreement with Puration is game-changing. GNBT will be introducing NuGenerex CBD HydroHealth High Alkaline Water to its patient population and ever-growing pharmacy network. This high value new offering will be infused with custom CBD extracts as therapies for symptoms of specific health issues. “
Goldman concluded, “The aforementioned business development events projects affirm our favorable outlook on these shares and we continue to expect a higher overall valuation ahead for GNBT.”
(0)
(0)